Adverum Biotechnologies Inc
(NASDAQ : AAVL)

( )
AAVL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.43%89.631.3%$877.94m
AMGNAmgen Inc.
0.40%191.891.2%$550.47m
GILDGilead Sciences, Inc.
0.50%64.920.9%$461.62m
BIIBBiogen Inc.
-29.23%226.881.3%$457.10m
ONCESpark Therapeutics, Inc.
-0.20%113.2711.2%$443.03m
REGNRegeneron Pharmaceuticals, Inc.
-0.72%402.592.6%$280.51m
ILMNIllumina, Inc.
1.24%319.213.5%$280.06m
VRTXVertex Pharmaceuticals Incorporated
1.43%182.561.9%$232.81m
SRPTSarepta Therapeutics, Inc.
2.27%126.6615.4%$211.90m
EXASExact Sciences Corporation
1.70%92.0225.3%$191.93m
ALXNAlexion Pharmaceuticals, Inc.
1.94%134.212.0%$186.57m
BPTHBio-Path Holdings, Inc.
-14.05%18.48190.1%$182.12m
AAgilent Technologies, Inc.
1.34%82.001.6%$143.35m
IONSIonis Pharmaceuticals, Inc.
0.36%80.508.3%$105.13m
BMRNBioMarin Pharmaceutical Inc.
0.91%90.784.3%$95.05m

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.